Use of the EsoGuard® Molecular Biomarker Test in Non-Endoscopic Detection of Barrett’s Esophagus among High-Risk Individuals in a Screening Population
medRxiv – June 24, 2024
Source: medRxiv/bioRxiv/arXiv
Summary
Barrett's Esophagus can lead to serious health issues, yet early detection is challenging. This study highlights the EsoGuard test, which effectively identifies high-risk individuals for Barrett’s Esophagus without invasive procedures. Using a non-endoscopic approach, it demonstrated strong performance and safety, offering a promising screening tool for those with chronic reflux and additional risk factors.
Abstract
Background and Aims Barrett’s Esophagus (BE) is the precursor to esophageal adenocarcinoma (EAC). We aimed to assess performance, safety, and tolerability of the EsoGuard (EG) assay on samples collected non-endoscopically with the EsoCheck (EC) device (EG/EC) for BE detection in the intended-use population, meeting American College of Gastroenterology (ACG) guideline criteria (chronic gastroesophageal reflux disease (GERD) and 3+ additional risk factors).